HeartBeam (NASDAQ: BEAT) was featured in a recent article that discussed Joseph Gunnar & Co.’s upgrade of the company from Hold to Buy and raising of its 12-month price target to $4 from $1, citing regulatory progress and the company’s transition toward commercialization. The piece reads, “‘We upgrade HeartBeam to a BUY and High-Risk rating with a raised price target of $4 (from $1), reflecting progress in cardiac risk detection,’ the February 2026 report states. The report highlights a significant turning point for the company following FDA clearance of its 12-lead ECG synthesis software in December 2025 for arrhythmia assessment, which resolved an earlier regulatory setback and allowed HeartBeam to transition to commercial-stage status.”
To view the full article, visit https://ibn.fm/NrrYt
In brief
HeartBeam says it was featured in an article discussing the company’s regulatory progress and move toward commercialization. The article describes FDA clearance in December 2025 for HeartBeam’s 12-lead ECG synthesis software for arrhythmia assessment, which it says resolved an earlier regulatory setback and enabled a transition to commercial-stage status. The company develops portable cardiac technology intended to capture electrical signals from three dimensions and provide cardiac information outside medical facilities. HeartBeam says its platform is designed to help physicians identify cardiac trends and acute conditions and guide patients to appropriate care. The company also reports holding 13 U.S. patents and 4 international-issued patents related to its technology.
Key takeaways
- HeartBeam says an article covered its regulatory progress and transition toward commercialization.
- The company reports FDA clearance in December 2025 for its 12-lead ECG synthesis software for arrhythmia assessment.
- HeartBeam describes its platform as cable-free technology for capturing the heart’s electrical signals from three dimensions.
- The company reports 13 U.S. and 4 international-issued patents related to its technology.
About HeartBeam Inc.
HeartBeam is a medical technology company dedicated to transforming cardiac care by providing powerful cardiac insights wherever the patient is. The company is creating the first-ever cable-free 12-lead ECG capable of capturing the heart’s electrical signals from three dimensions. This platform technology is designed to be used in portable devices that can be used wherever the patient is to deliver actionable heart intelligence. Physicians will be able to identify cardiac health trends and acute conditions and direct patients to the appropriate care — all outside of a medical facility, thus redefining the future of cardiac health management. The company holds 13 U.S. and 4 international-issued patents related to technology enablement. For more information, visit www.HeartBeam.com.
NOTE TO INVESTORS: IBN is a multifaceted financial news, content creation and publishing company utilized by both public and private companies to optimize investor awareness and recognition. For more information, please visit https://www.InvestorBrandNetwork.com
Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://IBN.fm/Disclaimer
The latest news and updates relating to BEAT are available in the company’s newsroom at https://ibn.fm/BEAT
Corporate Communications
IBN
Austin, Texas
www.InvestorBrandNetwork.com
512.354.7000 Office
[email protected]
Questions around this news
What regulatory progress did HeartBeam report?
The release says the FDA cleared HeartBeam’s 12-lead ECG synthesis software in December 2025 for arrhythmia assessment. It describes that clearance as resolving an earlier regulatory setback and enabling the company to move into commercial-stage status. The release does not provide further details about the clearance or the software’s use.
What does HeartBeam’s cable-free ECG technology aim to do?
The release describes a platform intended for portable devices that capture the heart’s electrical signals from three dimensions. It says physicians could use the resulting information to monitor cardiac health trends and identify acute conditions outside a medical facility, helping guide patients toward appropriate care. These are the company’s stated aims for the technology.
What does the release mean by HeartBeam’s move to commercial-stage status?
The release links the company’s move to commercial-stage status to FDA clearance of its software. It also says the company is transitioning toward commercialization. It does not specify when products will be available, whether sales have begun, or what commercial activities are planned, so the phrase should not be taken as confirmation of those details.
What is a 12-lead ECG?
An ECG, or electrocardiogram, records electrical activity generated by the heart. A 12-lead ECG presents that activity from multiple viewpoints, using electrodes placed on the body. Clinicians can examine the resulting patterns as part of assessing heart rhythm and other cardiac concerns; an ECG is one source of information in a broader medical evaluation.
SEC filings
- 4Insider transaction Filed
- 4Insider transaction Filed
- 4Insider transaction Filed
- 4Insider transaction Filed
- 4Insider transaction Filed
- 4Insider transaction Filed
- 4Insider transaction Filed
- 4Insider transaction Filed
- 4Insider transaction Filed
- 4Insider transaction Filed
- EFFECTEFFECT Filed
- CORRESPCORRESP Filed
- S-3/AAMENDMENT NO. 1 TO FORM S-3 Filed
- 10-KAnnual report Filed
Earlier from HeartBeam Inc.
- HeartBeam (NASDAQ: BEAT) Partners with Mount Sinai to Accelerate AI-ECG Development and Validation
- HeartBeam (NASDAQ: BEAT) Reports Q4 and Full-Year 2025 Results, Advances Commercialization and Clinical Development
- HeartBeam (NASDAQ: BEAT) Collaborates With Mount Sinai to Advance AI-ECG Algorithm Development
- HeartBeam (NASDAQ: BEAT) Management to Participate in March 2026 Investor and Industry Conferences
- HeartBeam (NASDAQ: BEAT) Enrolls First Patients in ALIGN-ACS Pilot Study for Heart Attack Detection
